Trial Profile
A Phase 1, Open-Label, Dose Ascending Study to Evaluate the Safety and Tolerability of the Therapeutic Radiopharmaceutical 131I-MIP-1095 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs LNTH 1095 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 03 Apr 2019 Status changed from active, no longer recruiting to completed.
- 01 Aug 2018 Planned number of patients changed from 40 to 10.
- 01 Aug 2018 Status changed from recruiting to active, no longer recruiting.